Trevi Therapeutics Inc (TRVI) Stock Price, Quote & News

Latest News on TRVI

Apr 3, 2025, 7:30 AM EDT - 20 days ago

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Mar 18, 2025, 6:47 PM EDT - 5 weeks ago

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 5 weeks ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Mar 11, 2025, 4:05 PM EDT - 6 weeks ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Mar 10, 2025, 11:30 AM EDT - 6 weeks ago

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

$Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 10, 2025, 6:00 AM EDT - 6 weeks ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

$Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 9, 2025, 4:00 PM EDT - 6 weeks ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Feb 27, 2025, 7:30 AM EST - 7 weeks ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 7:30 AM EST - 2 months ago

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Jan 30, 2025, 7:30 AM EST - 2 months ago

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Jan 8, 2025, 7:30 AM EST - 3 months ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:36 AM EST - 4 months ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Dec 12, 2024, 9:47 AM EST - 4 months ago

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Dec 12, 2024, 7:30 AM EST - 4 months ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Dec 3, 2024, 4:05 PM EST - 5 months ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Nov 21, 2024, 7:30 AM EST - 5 months ago

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 11:54 PM EST - 6 months ago

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 6 months ago

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 30, 2024, 4:05 PM EDT - 6 months ago

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

$Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough$

Oct 21, 2024, 7:30 AM EDT - 6 months ago

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Oct 15, 2024, 7:30 AM EDT - 6 months ago

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Oct 3, 2024, 4:05 PM EDT - 7 months ago

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

Sep 30, 2024, 5:30 PM EDT - 7 months ago

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.

Sep 26, 2024, 7:30 AM EDT - 7 months ago

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Sep 4, 2024, 4:05 PM EDT - 8 months ago

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Aug 28, 2024, 7:30 AM EDT - 8 months ago

Trevi Therapeutics to Participate in September Investor and Medical Conferences

Aug 11, 2024, 1:28 AM EDT - 9 months ago

Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 9 months ago

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

Aug 1, 2024, 7:30 AM EDT - 9 months ago

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024

Jul 2, 2024, 7:30 AM EDT - 10 months ago

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events

May 11, 2024, 1:56 PM EDT - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming Conferences

May 7, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 1, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming April Events

Apr 2, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

Mar 20, 2024, 6:21 PM EDT - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024

Feb 28, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Upcoming March Events

Feb 6, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 4, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics Provides Business Updates

Dec 5, 2023, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

Nov 12, 2023, 5:46 AM EST - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 4:05 PM EST - 1 year ago

Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update

$Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough$

Nov 2, 2023, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough

Nov 1, 2023, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023

Oct 13, 2023, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis

Sep 6, 2023, 7:30 AM EDT - 1 year ago

Market Cap	586.86M
Revenue (ttm)	0.00
Net Income (ttm)	-47.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,226,800
Avg Vol	2,578,088
Day's Range	N/A - N/A
Shares Out	96.68M
Stochastic %K	89%
Beta	0.41
Analysts	Strong Sell
Price Target	$19.06